Antipruritic Effect of Azathioprine in Atopic Dermatitis: A Pilot Study



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

背景： 尽管目前有多种治疗特应性皮炎的方法，但如何有效控制包括瘙痒在内的主要症状仍然是一项重要的临床挑战。硫唑嘌呤作为一种全身性免疫调节剂，被认为是标准治疗效果不佳患者的潜在治疗选择。

目的：评价硫唑嘌呤对特应性皮炎患者的止痒效果。

方法： 本研究纳入10例年龄在18至60岁之间的特应性皮炎患者，这些患者均伴有持续性、临床显著的瘙痒，且对标准治疗无效。所有患者均接受口服硫唑嘌呤治疗，剂量为每日100毫克，连续服用10天，同时保持常规基础皮肤护理。

结果：治疗显著降低了瘙痒强度：瘙痒指数（PI）值在一天中的所有时间点（早晨、下午、晚上）均下降了74%至78%。研究者总体评估（IGA）评分从2.8分降至1.6分。此外，还观察到血清IgE水平降低以及炎症性皮肤改变的严重程度减轻。

结论：硫唑嘌呤在特应性皮炎患者中表现出显著的止痒效果，可迅速改善临床症状。这些发现支持进一步研究硫唑嘌呤作为治疗特应性皮炎难治性瘙痒的有效疗法。

Full Text

Restricted Access

About the authors

Nikolay G. Kochergin

Clinic of Skin and Venereal Diseases named after V. A. Rakhmanov

Email: nkocha@yandex.ru
ORCID iD: 0000-0001-7136-4053

Dr. Sci (Med), Professor

Yingyu Ding

Clinic of Skin and Venereal Diseases named after V. A. Rakhmanov

Author for correspondence.
Email: dininyui@yandex.ru
ORCID iD: 0009-0002-2342-276X

Postgraduate student of the Department of Skin and Venereal Diseases

China

Kristina A. Myzina

Clinic of Skin and Venereal Diseases named after V. A. Rakhmanov

Email: bashlakova.kristina@mail.ru
ORCID iD: 0000-0002-9628-0523

PhD (Med)

References

  1. Yosipovitch G, Papoiu AD. What causes itch in atopic dermatitis? Curr Allergy Asthma Rep. 2008;8(4):306–311. doi: 10.1007/s11882-008-0049-z.
  2. Frazier W, Bhardwaj N. Atopic dermatitis: Diagnosis and treatment. Am Fam Physician. 2020;101(10):590–598.
  3. Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol. 2018;19(3):319–332. doi: 10.1007/s40257-017-0335-4.
  4. Leis-Dosil VM, Prats-Caelles I. Practical management of immunosuppressants in dermatology. Actas Dermosifiliogr (Engl Ed). 2018;109(1):24–34. doi: 10.1016/j.ad.2017.05.005.
  5. Chavez-Alvarez S, Herz-Ruelas M, Villarreal-Martinez A, Ocampo-Candiani J, Garza-Garza R, Gomez-Flores M. Azathioprine: Its uses in dermatology. An Bras Dermatol. 2020;95(6):731–736. doi: 10.1016/j.abd.2020.05.003.
  6. Garritsen FM, van den Heuvel JM, Bruijnzeel-Koomen CAFM, Maitland-van der Zee AH, van den Broek MPH, de Bruin-Weller MS. Use of oral immunosuppressive drugs in the treatment of atopic dermatitis in the Netherlands. J Eur Acad Dermatol Venereol. 2018;32(8):1336–1342. doi: 10.1111/jdv.14896.
  7. Roblin X, Oussalah A, Phelip JM, Peyrin-Biroulet L. Azathioprine metabolism: What to do or not to do in clinical practice? Gastroenterol Clin Biol. 2009;33(3):172–175. doi: 10.1016/j.gcb.2008.12.005.
  8. Roekevisch E, Schram ME, Leeflang MMG, et al. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data. J Allergy Clin Immunol. 2018;141(2):825–827.e10. doi: 10.1016/j.jaci.2017.09.033.
  9. Schram ME, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. Journal of Allergy and Clinical Immunology. 2011;128(2):353–359.
  10. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20(8):1149–1157. doi: 10.1111/j.1440-1746.2005.03832.x.
  11. Oetjen LK, Kim BS. Interactions of the immune and sensory nervous systems in atopy. FEBS J. 2018;285(17):3138–3151. doi: 10.1111/febs.14465.
  12. Roesner LM, Werfel T, Heratizadeh A. The adaptive immune system in atopic dermatitis and implications on therapy. Expert Rev Clin Immunol. 2016;12(7):787–796. doi: 10.1586/1744666X.2016.1165093.
  13. Bağci IS, Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3):858–866. doi: 10.1016/j.jaci.2017.10.045.
  14. Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021;8:638325. doi: 10.3389/fmed.2021.638325.
  15. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: The past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369–389. doi: 10.1016/j.jaad.2005.07.059.
  16. de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med. 2005;63(11):444–446.
  17. Olisova O, Shimanovskiy N, Dukhanin A, Teplyuk N, Lepekhova A. Development of azathioprine-based treatment regimen for patients with steroid-resistant pemphigus. Almanac of Clinical Medicine. 2016;44:6–12.
  18. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris: A long-term follow-up. J Am Acad Dermatol. 1987;16(3 Pt 1):527–533. doi: 10.1016/S0190-9622(87)70069-3.
  19. Beissert S, Werfel T, Frieling U, et al. Oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143(12):1536–1542. doi: 10.1001/archderm.143.12.1536.
  20. Gupta R. Prolonged remission of psoriasis with azathioprine pulse therapy. Indian J Dermatol. 2015;60(4):360–363. doi: 10.4103/0019-5154.160480.
  21. Verma KK, Kumar P, Bhari N, Gupta S, Kalaivani M. Azathioprine weekly pulse versus methotrexate for the treatment of chronic plaque psoriasis. Indian J Dermatol Venereol Leprol. 2021;87(4):509–514. doi: 10.25259/IJDVL_718_18.
  22. Pathania YS, Bishnoi A, Parsad D, Kumar A, Kumaran MS. Comparing azathioprine with cyclosporine in the treatment of antihistamine-refractory chronic spontaneous urticaria. World Allergy Organ J. 2019;12(5):100033. doi: 10.1016/j.waojou.2019.100033.
  23. Olisova OY, Vovdenko KA, Kayumova LN, Koteneva PI, Lomonosov KM. NB-UVB and azathioprine combined therapy for patients with non-segmental vitiligo. Exp Dermatol. 2024;33(2):e15039. doi: 10.1111/exd.15039.
  24. Nagar R, Mandloi U, Singh M, Dubey S, Khare S. Effectiveness and safety of azathioprine versus PUVA-SOL as steroid-sparing agents in the treatment of unstable vitiligo. Skinmed. 2024;22(4):276–280.
  25. Jawade S, Saoji V, Madke B, Singh A. Comparison of oral azathioprine and oral mini-pulse steroid in the treatment of vitiligo. Indian J Dermatol. 2023;68(6):591–597. doi: 10.4103/ijd.ijd_865_22.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.